At 13.1% CAGR, the Middle East & Africa Neurotoxins Market is projected to be worth US$ 355.20 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa neurotoxins market was valued at US$ 192.00 million in 2023 and is expected to reach US$ 355.20 million by 2028, registering a CAGR of 13.1% from 2023 to 2028. Emergence of innovative facial aesthetic products and BOTA for assisted reproductive technology (ART) are the critical factors attributed to the Middle East & Africa neurotoxins market expansion.                    

The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of "DTX-021"—a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the Middle East & Africa neurotoxin market to grow.

On the contrary, improper/inappropriate injection technique hurdles the growth of Middle East & Africa neurotoxins market.

Based on product type, the Middle East & Africa neurotoxins market is segmented into botox, dysport, xenomin, and others. The botox segment held 67.7% market share in 2023, amassing US$ 130.01 million. It is projected to garner US$ 235.76 million by 2028 to expand at 12.6% CAGR during 2023–2028.

Based on application, the Middle East & Africa neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held 50.6% market share in 2023, amassing US$ 97.15 million. It is projected to garner US$ 178.26 million by 2028 to expand at 12.9% CAGR during 2023–2028.

Based on end user, the Middle East & Africa neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held 52.4% market share in 2023, amassing US$ 100.53 million. It is projected to garner US$ 187.38 million by 2028 to expand at 13.3% CAGR during 2023–2028.

Based on country, the Middle East & Africa neurotoxins market has been categorized into Saudi Arabia, the UAE, South Africa, and the rest of the Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 32.6% market share in 2023. It was assessed at US$ 62.51 million in 2023 and is likely to hit US$ 117.61 million by 2028, exhibiting a CAGR of 13.5% during the forecast period.     

Key players dominating the Middle East & Africa neurotoxins market are AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA among others.   

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com